Seeking Alpha

Seeking Alpha Portfolio App for iPad

Ben Yoffe

Ben Yoffe picture

Ben Yoffe

Profile

Send Message

View as an RSS Feed

View Ben Yoffe's Articles BY TICKER:

These 2 Biotechs May Surprise Investors, Says Janney Analyst Kimberly Lee
on Wed, Jun 12 • CORT, FOLD • 3 Comments
GW Pharmaceuticals: Giving New Meaning To 'High Potential'
on Mon, Jun 10 • GWPH • 2 Comments
Canaccord Genuity Sees Strong Upside In Venaxis' Shares And Set A $7 Price Target
on Thu, Jun 6 • APPY • 6 Comments
Sucampo's Stock Could Reach $12, Says Maxim's Senior Vice President
on Thu, May 9 • SCMP • Comment!
These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst
on Mon, Mar 25 • ARQL, NAVB, SRPT • 4 Comments
Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip
on Fri, Mar 1 • SNTS, DEPO • Comment!
AVEO: Final Overall Survival Results From The TIVO1 Study
on Wed, Feb 13 • AVEO • 3 Comments
IntelGenx CEO Provides Insight Into The Company's Catalysts
on Tue, Feb 5 • IGXT.OB • 4 Comments
Maxim Group Sees 350% Upside In Shares Of Omeros Corporation
on Mon, Feb 4 • OMER • 6 Comments
William Blair Analysts Are Gaining Comfort Ahead Of Dynavax's Heplisav PDUFA
on Mon, Jan 14 • DVAX • 13 Comments
Vivus Still Needs The Help Of A Big Pharma Partner, Say Cowen's Analysts
on Mon, Jan 7 • VVUS • 16 Comments
Exclusive Interview With John Varian, XOMA Corporation CEO
on Thu, Jan 3 • XOMA • 2 Comments
Roth Capital Expects FDA Approval For Alexza's Adasuve
on Thu, Dec 20, 2012 • ALXA • 5 Comments
Cowen Maintains An Outperform On Hyperion Therapeutics
on Mon, Dec 10, 2012 • HPTX • 2 Comments
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid
on Tue, Dec 4, 2012 • ASTM, CUR, PSTI • 36 Comments
Analysts At William Blair Maintain Outperform On Dynavax Technologies
on Mon, Nov 5, 2012 • DVAX • 1 Comment
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior Analyst
on Thu, Oct 25, 2012 • DVAX • 10 Comments
Interview: Delcath's CEO Provides Details About The Resubmission Of The FDA's New Drug Application For CHEMOSAT
on Wed, Oct 3, 2012 • ANGO, ATRS, DCTH • 7 Comments
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
on Fri, Sep 28, 2012 • DCTH • 4 Comments
MLV & Co Sees 146% Upside For Dynavax Technologies' Shares
on Wed, Sep 5, 2012 • AZN, GSK, MRK • 19 Comments
Maxim Group Highlights 3 Biotech Stocks With Key Milestones Ahead
on Fri, Aug 24, 2012 • EXEL, MDGN, ARIA • 1 Comment
Raptor Pharmaceuticals: An Interview With ThinkEquity
on Mon, Aug 20, 2012 • MYL, RPTP • Comment!
Alexza Pharmaceuticals Reiterated With An Outperform At JMP Securities
on Fri, Aug 10, 2012 • APPA.OB, APRI, VVUS • 10 Comments
WBB Securities Recommends Alexza Pharmaceuticals As A Strong Buy
on Fri, Aug 3, 2012 • ALXA • 5 Comments
Alexza's CEO Has High Expectations Of Receiving FDA Approval For Adasuve
on Mon, Jul 30, 2012 • ALXA • 2 Comments
JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103
on Wed, Jul 25, 2012 • MYL, RPTP • 9 Comments
Cowen And Company Expect FDA Approval For Rayos
on Mon, Jun 18, 2012 • AZN, PRX, HZNP • 3 Comments
Navidea's Share Price Could Double This Year
on Tue, May 29, 2012 • CAH, NAVB • 7 Comments
Stifel Nicolaus Sees An Opportunity In Horizon Pharma Shares
on Tue, May 8, 2012 • PRX, HZNP • Comment!
Protalix's Regulatory Approval: Analyst Q&A
on Wed, Mar 7, 2012 • PLX • 1 Comment
Protalix BioTherapeutics: It's All About The Technology
on Tue, Jan 31, 2012 • PFE, TEVA, PLX • 1 Comment